(S)-1-(1-(4-chlorophenyl)-2-methyl-1H-imidazol-4-yl)ethanamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (S)-1-(1-(4-chlorophenyl)-2-methyl-1H-imidazol-4-yl)ethanamine
• 英文别名: (S)-1-(1-(4-chlorophenyl)-2-methyl-1H-imidazol-4-yl)ethylamine；(1S)-1-[1-(4-chlorophenyl)-2-methylimidazol-4-yl]ethanamine
• 化学式: C₁₂H₁₄ClN₃
• 分子量: 235.716
• InChiKey: WRDZUUSOARMBSI-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
  申请人：NOVARTIS AG

  公开号：US20150152093A1

  公开（公告）日：2015-06-04

  The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2a , R 2b and R 3 -R 7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  该发明涉及一种公式(I)或其药学上可接受的盐，其中R1、R2a、R2b和R3-R7如下。该发明还涉及含有公式(I)化合物的组合物，并且涉及使用这些化合物来抑制具有新型活性的突变IDH蛋白质。该发明进一步涉及使用公式(I)化合物来治疗与这种突变IDH蛋白质相关的疾病或障碍，包括但不限于细胞增殖障碍，如癌症。
• COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF
  申请人：Shanghai Haihe Pharmaceutical Co., Ltd.

  公开号：EP3434674A1

  公开（公告）日：2019-01-30

  Provided in the present invention are a compound having the effects of preventing and treating diseases related to IDH mutation, and a preparation method and use thereof. In particular, provided in the present invention are the compound as shown in formula (I), a stereoisomer, a racemic body or a pharmaceutically acceptable salt thereof, and the use thereof in preparing drugs for preventing and treating diseases related to IDH mutation

  本发明提供了一种具有预防和治疗 IDH 突变相关疾病效果的化合物及其制备方法和用途。特别是，本发明提供了式 (I) 所示的化合物、其立体异构体、外消旋体或药学上可接受的盐，以及其在制备预防和治疗 IDH 突变相关疾病的药物中的用途。
• Compound having mutant IDH inhibitory activity, preparation method and use thereof
  申请人：SHANGHAI HAIHE PHARMACEUTICAL CO., LTD.

  公开号：US10682352B2

  公开（公告）日：2020-06-16

  Provided in the present invention are a compound having the effects of preventing and treating diseases related to IDH mutation, and a preparation method and use thereof. In particular, provided in the present invention are the compound as shown in formula (I), a stereoisomer, a racemic body or a pharmaceutically acceptable salt thereof, and the use thereof in preparing drugs for preventing and treating diseases related to IDH mutation

  本发明提供了一种具有预防和治疗 IDH 突变相关疾病效果的化合物及其制备方法和用途。特别是，本发明提供了式 (I) 所示的化合物、其立体异构体、外消旋体或药学上可接受的盐，以及其在制备预防和治疗 IDH 突变相关疾病的药物中的用途。
• [EN] COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF<br/>[FR] COMPOSÉ AYANT UNE ACTIVITÉ INHIBITRICE DE L'IDH MUTÉE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 一种具有突变型IDH抑制活性的化合物、其制备方法及用途
  申请人：SHANGHAI HAIHE PHARMACEUTICAL CO LTD

  公开号：WO2017162133A1

  公开（公告）日：2017-09-28

  本发明提供了一种具有预防和治疗与IDH突变相关的疾病的化合物、其制备方法和用途。具体地，本发明提供了式(I)化合物、其立体异构体、外消旋体、或其药学上可接受的盐，并提供了其在制备用于预防和治疗与IDH突变相关的疾病的药物中的应用。
• ((4-(2-OXOIMIDAZOLIDINE-1-YL)PYRIMIDIN-2-YL)AMINE DERIVATIVES AS MUTANT IDH INHIBITORS FOR TREATING CANCER
  申请人：Shanghai Haihe Pharmaceutical Co., Ltd.

  公开号：EP3434674B1

  公开（公告）日：2021-02-24